Aligos Therapeutics
Clinical trials sponsored by Aligos Therapeutics, explained in plain language.
Clinical-stage biopharmaceutical company developing antiviral therapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hepatitis b drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis Phase 2 study tests an experimental drug called ALG-000184 against a standard hepatitis B medication (tenofovir) in 200 adults with chronic hepatitis B. Participants take one pill daily for 48 weeks. The main goal is to see if the new drug can lower hepatitis B virus levels …
Phase: PHASE2 • Sponsor: Aligos Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Kidney function may change how hepatitis b drug works
Knowledge-focused Recruiting nowThis early study tests a single dose of the drug pevifoscorvir in 30 people with chronic hepatitis B, some with kidney problems and some with healthy kidneys. Researchers want to see how kidney function affects drug levels and safety. The goal is to learn how to dose the drug pro…
Phase: PHASE1 • Sponsor: Aligos Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New hepatitis b drug studied in Liver-Impaired patients
Knowledge-focused Recruiting nowThis early-stage study tests a single dose of the drug pevifoscorvir sodium in 16 adults: 8 with moderate liver impairment and 8 healthy volunteers. Researchers want to see how the drug is processed in the body and if it is safe. The goal is to gather information for future dosin…
Phase: PHASE1 • Sponsor: Aligos Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC